In minimal disease they won't work especially in tumors that are relatively antigenically silent I,e PANC. Trial after trial have failed. Perhaps if we can figure out how to efficiently expand T cell clones in Vivo then maybe but until then I stand by my comment that cancer vaccines will fail and will especially fail in a minimal disease setting,
Ok I'll bite. I always enjoy arguing with self proclaimed "experts" on message boards. Do tell me Mr Gene what comment that I posted was so ridiculous? It is a fact you can not have cytotoxic T cell expansion without the presence of antigens. Remember its an T Cell expansion is via an autocrine response that is at its core dependent on antigens.
Check point inhibitors work because they don't rely on T cell clonal expansion. Fundamentally the immune system wants to fight the cancer but the cancer has learned to evade this by over expressing the T cell co receptor PDL1 which puts the brakes on. Check point inhibitors releases this brake.
its a double edge though, vaccines can't work if you never get T cell expansion and you are unlikely to get T Cell expansion if the antigen is rare i.e. minimal disease. This is why imo cancer vaccines will not work.
Yes I'm aware of VLP based vaccines and companies that have tried to use them before I.e. novavax. Still he same basic problem exists. You have to rely on the immune system to expand antigen specific cytotoxic T cells in Vivo. Not gonna happen. We've tested this multiple times using multiple different systems that latest of which is hyperacute vaccine.
I think in the long-term that valuation is accurate assuming the IDO platform doesn't follow the same path as hyperacute. I'm more excited about their IDO platform anyway but this stock will be tainted for many months. Expect data out at ASCO on IDO. Abstracts will be released on May 18th and we should see a modest pop from this. There's a lot of growing buzz around the combo trial with AG and indoximod in PANC.
Yes but it's still a distraction and they will still incur legal fees. at this point they may be best selling off the Ido and restructuring to just a infectious disease company,
If there were any doubt left IMPRESS has hammered the final nail into this coffin. Cancer Vaccines are dead end of story. You simply can not give a vaccine regardless of the form and expect T cell clonal expansion to any significant amount. Not to mention Pancreatic cancer is relatively antigenically silent. There's a reason why vaccines have only worked (minimally) in the most antigenic tumors i.e. melanoma.
that's over a million investment. May I ask what on earth were you thinking? I was confident as well on this one but that's a lot to risk on a binary event. I sincerely hope you have that kind of money to loose.
Ok that wasn't even close at all. Shockingly failed with no sign of efficacy whatsoever. I've said this before but but now the class action suits will start. This was extremely careless of management to lead to strongly towards success. They couldn't have been his inept. Could they?
I believe I've said before that I always assume the news is leaked and the direction of the market is the sum total of that leaked news. Hopefully it doesn't play out
If it follows like every other biotech I've been in it will run up after news release of positive data and sell off after approval.
Well technically couldn't the final even has happened but the data is under review by the DMC. The company would still technically be blinded still.
I listened to the audio finally. They repeatedly said they are still blinded to the study and do not know he results yet. Is it safe to assume then the final event has not yet happened?